መነሻ › ሙያዎች › Molecular and Cellular Biologists › Princeton, NJ
Molecular and Cellular Biologists በPrinceton፣ NJ፡ የH-1B ደመወዞች
72 የሥራ ሁኔታ ማመልከቻዎች ለዚህ ሙያ ከሥራ ቦታ ጋር በPrinceton፣ NJ። መካከለኛ የቀረበ መሠረታዊ ደመወዝ $100,000፤ መካከለኛ ግማሽ $77,250–$140,000።
ማመልከቻዎች (LCAs)72
መካከለኛ የሚቀርብ ደመወዝ$100,000
የደመወዞች መካከለኛ ግማሽ$77,250–$140,000
ከ10ኛ እስከ 90ኛ ፐርሰንታይል$69,600–$159,700
በደመወዝ ደረጃ
| የደመወዝ ደረጃ | መካከለኛ ደመወዝ |
|---|---|
| ደረጃ I (መግቢያ) | $70,788 |
| ደረጃ II (ብቁ) | $97,250 |
| ደረጃ III (ልምድ ያለው) | $147,093 |
| ደረጃ IV (ሙሉ ብቃት ያለው) | $148,000 |
የሥራ ሚኒስቴር ለእያንዳንዱ ሙያ እና አካባቢ ከደረጃ I (መግቢያ) እስከ ደረጃ IV (ሙሉ በሙሉ ብቁ) ድረስ አራት የሚገባ ደመወዝ ደረጃዎችን ይወስናል። አሠሳሪው ከሥራው መስፈርቶች ጋር የሚስማማውን ደረጃ ይመርጣል።
አሠሪዎች
| አሠሪ | LCAs | መካከለኛ ደመወዝ |
|---|---|---|
| The Trustees of Princeton University | 29 | $71,000 |
| Bristol-Myers Squibb Company | 21 | $147,994 |
| Howard Hughes Medical Institute | 6 | $88,920 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 2 | $130,174 |
| ArrePath, Inc. | 2 | $85,000 |
| Accurant Biotech, Inc. | 2 | $79,500 |
| Camurus Inc | 2 | $145,000 |
| Zifo Technologies, Inc | 1 | $94,500 |
| E.R. Squibb & Sons, LLC | 1 | $121,512 |
| Evotec (US), Inc. | 1 | $83,000 |
| Textile Research Institute | 1 | $80,000 |
| CHDI Management, Inc. | 1 | $106,090 |
| AskPharma lnc. | 1 | $80,000 |
| Moderna Services, Inc. | 1 | $159,700 |
| ModernaTX, Inc. | 1 | $159,700 |
የሥራ መደቦች
- Postdoctoral Research Associate18
- Associate Research Scholar4
- Manager, Statistical Programming4
- Senior Manager, Clinical Data Management3
- Senior Manager, Statistical Programming3
- Associate Professional Specialist3
- Research Specialist II3
- Clinical Data Scientist2
- Research Programmer I2
- Research Specialist2
- Scientist2
- Manager, Case Management E2E2
- Scientist II2
- Postdoctoral Research Fellow2
- Senior Manager, Pharmacovigilance Operations2
ደመወዞች በእያንዳንዱ ማመልከቻ ላይ በተገለጸው ደመወዝ ዝቅተኛ ጫፍ ሲሆኑ ወደ ዓመታዊ መጠን ተቀይረዋል፤ ስታቲስቲክሶች የተረጋገጡ ሙሉ ጊዜ ማመልከቻዎችን ብቻ ይጠቀማሉ። LCA የቪዛ ማረጋገጫ አይደለም፤ አንድ LCA ለብዙ ቦታዎች ሊሸፍን ይችላል። ምንጭ፡ የአሜሪካ የሥራ ሚኒስቴር፣ OFLC LCA መረጃ ማሳያ መረጃ፣ የፋይናንስ ዓመታት 2023–2026 (የቅርብ ጊዜ ውሳኔ 30 ጁን 2026)።